---
document_datetime: 2025-11-23 08:01:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/atosiban-sun.html
document_name: atosiban-sun.html
version: success
processing_time: 0.1132916
conversion_datetime: 2025-12-23 23:05:51.449117
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Atosiban SUN

[RSS](/en/individual-human-medicine.xml/67088)

##### Authorised

This medicine is authorised for use in the European Union

atosiban

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Atosiban SUN](#more-information-on-atosiban-sun-1532)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Atosiban SUN. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Atosiban SUN.

For practical information about using Atosiban SUN, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Atosiban SUN and what is it used for?

Atosiban SUN is a medicine that contains the active substance atosiban. It is used to delay birth in adult women who are 24 to 33 weeks pregnant, when they show signs that they may give birth pre-term (prematurely). These signs include:

- regular contractions lasting at least 30 seconds at a rate of at least four every 30 minutes;
- dilation of the cervix (the neck of the womb) of 1 to 3 cm and an effacement (a measure of the thinness of the cervix) of 50% or more.

In addition, the baby must have a normal heart rate.

Atosiban SUN is a 'generic medicine'. This means that Atosiban SUN is similar to a 'reference medicine' already authorised in the European Union (EU) called Tractocile.

## How is Atosiban SUN used?

Atosiban SUN can only be obtained with a prescription. Treatment with Atosiban SUN should be carried out by a doctor who has experience in the treatment of pre-term labour.

Treatment should be started as soon as possible after diagnosis of pre-term labour. Atosiban SUN is available as a solution for injection and as a concentrate that is made up into a solution for infusion (drip) into a vein. It is given into a vein in three stages, over a maximum of 48 hours: an initial injection into a vein (6.75 mg), followed by a high-dose infusion (18 mg per hour) over three hours, then a lower-dose infusion (6 mg per hour) lasting up to 45 hours. If contractions come back, treatment with Atosiban SUN can be repeated up to three more times during the pregnancy.

## How does Atosiban SUN work?

The active substance in Atosiban SUN, atosiban, is an antagonist of the natural hormone oxytocin. This means that atosiban blocks the action of oxytocin. Oxytocin is the hormone involved in starting contractions of the womb. By blocking the action of oxytocin, Atosiban SUN prevents contractions and causes the womb to relax, helping to delay birth.

## How has Atosiban SUN been studied?

The company provided data from the published literature on atosiban. No additional studies were needed as Atosiban SUN is a generic medicine that is given by infusion or injection and contains the same active substance as the reference medicine, Tractocile.

## What are the benefits and risks of Atosiban SUN?

Because Atosiban SUN is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Atosiban SUN approved?

The CHMP concluded that, in accordance with EU requirements, Atosiban SUN has been shown to have comparable quality and to be comparable to Tractocile. Therefore, the CHMP's view was that, as for Tractocile, the benefit outweighs the identified risk. The Committee recommended that Atosiban SUN be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Atosiban SUN?

A risk-management plan has been developed to ensure that Atosiban SUN is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Atosiban SUN, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Atosiban SUN

The European Commission granted a marketing authorisation valid throughout the European Union for Atosiban SUN on 31 July 2013.

Atosiban SUN : EPAR - Summary for the public

Reference Number: EMA/404586/2013

English (EN) (77.27 KB - PDF)

**First published:** 07/08/2013

**Last updated:** 07/08/2013

[View](/en/documents/overview/atosiban-sun-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-687)

български (BG) (130.28 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/bg/documents/overview/atosiban-sun-epar-summary-public_bg.pdf)

español (ES) (100.65 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/es/documents/overview/atosiban-sun-epar-summary-public_es.pdf)

čeština (CS) (124.49 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/cs/documents/overview/atosiban-sun-epar-summary-public_cs.pdf)

dansk (DA) (98.88 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/da/documents/overview/atosiban-sun-epar-summary-public_da.pdf)

Deutsch (DE) (102.07 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/de/documents/overview/atosiban-sun-epar-summary-public_de.pdf)

eesti keel (ET) (99.23 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/et/documents/overview/atosiban-sun-epar-summary-public_et.pdf)

ελληνικά (EL) (130.52 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/el/documents/overview/atosiban-sun-epar-summary-public_el.pdf)

français (FR) (101.23 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/fr/documents/overview/atosiban-sun-epar-summary-public_fr.pdf)

hrvatski (HR) (120.48 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/hr/documents/overview/atosiban-sun-epar-summary-public_hr.pdf)

italiano (IT) (99.34 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/it/documents/overview/atosiban-sun-epar-summary-public_it.pdf)

latviešu valoda (LV) (121.87 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/lv/documents/overview/atosiban-sun-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (124.68 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/lt/documents/overview/atosiban-sun-epar-summary-public_lt.pdf)

magyar (HU) (121.24 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/hu/documents/overview/atosiban-sun-epar-summary-public_hu.pdf)

Malti (MT) (125.48 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/mt/documents/overview/atosiban-sun-epar-summary-public_mt.pdf)

Nederlands (NL) (100.9 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/nl/documents/overview/atosiban-sun-epar-summary-public_nl.pdf)

polski (PL) (126.27 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/pl/documents/overview/atosiban-sun-epar-summary-public_pl.pdf)

português (PT) (100.74 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/pt/documents/overview/atosiban-sun-epar-summary-public_pt.pdf)

română (RO) (123.08 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/ro/documents/overview/atosiban-sun-epar-summary-public_ro.pdf)

slovenčina (SK) (124.77 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/sk/documents/overview/atosiban-sun-epar-summary-public_sk.pdf)

slovenščina (SL) (119.37 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/sl/documents/overview/atosiban-sun-epar-summary-public_sl.pdf)

Suomi (FI) (99.63 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/fi/documents/overview/atosiban-sun-epar-summary-public_fi.pdf)

svenska (SV) (77.29 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/sv/documents/overview/atosiban-sun-epar-summary-public_sv.pdf)

## Product information

Atosiban SUN : EPAR - Product Information

English (EN) (445.71 KB - PDF)

**First published:** 07/08/2013

**Last updated:** 20/06/2024

[View](/en/documents/product-information/atosiban-sun-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-724)

български (BG) (597.29 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/bg/documents/product-information/atosiban-sun-epar-product-information_bg.pdf)

español (ES) (446.03 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/es/documents/product-information/atosiban-sun-epar-product-information_es.pdf)

čeština (CS) (484.98 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/cs/documents/product-information/atosiban-sun-epar-product-information_cs.pdf)

dansk (DA) (492.71 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/da/documents/product-information/atosiban-sun-epar-product-information_da.pdf)

Deutsch (DE) (488.69 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/de/documents/product-information/atosiban-sun-epar-product-information_de.pdf)

eesti keel (ET) (454.11 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/et/documents/product-information/atosiban-sun-epar-product-information_et.pdf)

ελληνικά (EL) (564.7 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/el/documents/product-information/atosiban-sun-epar-product-information_el.pdf)

français (FR) (462.86 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/fr/documents/product-information/atosiban-sun-epar-product-information_fr.pdf)

hrvatski (HR) (487.9 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/hr/documents/product-information/atosiban-sun-epar-product-information_hr.pdf)

íslenska (IS) (461.64 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/is/documents/product-information/atosiban-sun-epar-product-information_is.pdf)

italiano (IT) (449.59 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/it/documents/product-information/atosiban-sun-epar-product-information_it.pdf)

latviešu valoda (LV) (509.75 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/lv/documents/product-information/atosiban-sun-epar-product-information_lv.pdf)

lietuvių kalba (LT) (515.12 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/lt/documents/product-information/atosiban-sun-epar-product-information_lt.pdf)

magyar (HU) (542.89 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/hu/documents/product-information/atosiban-sun-epar-product-information_hu.pdf)

Malti (MT) (630.82 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/mt/documents/product-information/atosiban-sun-epar-product-information_mt.pdf)

Nederlands (NL) (479.33 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/nl/documents/product-information/atosiban-sun-epar-product-information_nl.pdf)

norsk (NO) (445.38 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/no/documents/product-information/atosiban-sun-epar-product-information_no.pdf)

polski (PL) (503.34 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/pl/documents/product-information/atosiban-sun-epar-product-information_pl.pdf)

português (PT) (445.34 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/pt/documents/product-information/atosiban-sun-epar-product-information_pt.pdf)

română (RO) (557.09 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/ro/documents/product-information/atosiban-sun-epar-product-information_ro.pdf)

slovenčina (SK) (496.29 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/sk/documents/product-information/atosiban-sun-epar-product-information_sk.pdf)

slovenščina (SL) (512.35 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/sl/documents/product-information/atosiban-sun-epar-product-information_sl.pdf)

Suomi (FI) (462.79 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/fi/documents/product-information/atosiban-sun-epar-product-information_fi.pdf)

svenska (SV) (461.12 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

20/06/2024

[View](/sv/documents/product-information/atosiban-sun-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000170579 21/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Atosiban SUN : EPAR - All Authorised presentations

English (EN) (18.25 KB - PDF)

**First published:** 07/08/2013

**Last updated:** 07/08/2013

[View](/en/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-862)

български (BG) (40.29 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/bg/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_bg.pdf)

español (ES) (19.62 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/es/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.67 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/cs/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.38 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/da/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (19.42 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/de/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.56 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/et/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.76 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/el/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_el.pdf)

français (FR) (19.45 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/fr/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.9 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/hr/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (19.49 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/is/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.42 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/it/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.07 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/lv/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (34.14 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/lt/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.85 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/hu/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.13 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/mt/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (19.57 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/nl/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.37 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/no/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.38 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/pl/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.57 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/pt/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_pt.pdf)

română (RO) (36 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/ro/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.39 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/sk/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.6 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/sl/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (18.09 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/fi/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.5 KB - PDF)

**First published:**

07/08/2013

**Last updated:**

07/08/2013

[View](/sv/documents/all-authorised-presentations/atosiban-sun-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Atosiban SUN Active substance atosiban (as acetate) International non-proprietary name (INN) or common name atosiban Therapeutic area (MeSH) Obstetric Labor, Premature Anatomical therapeutic chemical (ATC) code G02CX01

### Pharmacotherapeutic group

Other gynecologicals

### Therapeutic indication

Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with:

- regular uterine contractions of at least 30 seconds' duration at a rate of ? 4 per 30 minutes;
- a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ? 50%;
- a gestational age from 24 until 33 completed weeks;
- a normal foetal heart rate.

## Authorisation details

EMA product number EMEA/H/C/002329

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Sun Pharmaceutical Industries Europe B.V.

Polarisavenue 87

Marketing authorisation issued 31/07/2013 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Atosiban SUN : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.23 KB - PDF)

**First published:** 20/06/2024

[View](/en/documents/procedural-steps-after/atosiban-sun-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Atosiban SUN : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (164.7 KB - PDF)

**First published:** 07/11/2013

**Last updated:** 09/02/2022

[View](/en/documents/procedural-steps-after/atosiban-sun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Atosiban SUN : EPAR - Public assessment report

Adopted

Reference Number: EMA/476499/2013

English (EN) (271.67 KB - PDF)

**First published:** 07/08/2013

**Last updated:** 07/08/2013

[View](/en/documents/assessment-report/atosiban-sun-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Atosiban SUN

Reference Number: EMA/CHMP/314586/2013

English (EN) (74.84 KB - PDF)

**First published:** 31/05/2013

**Last updated:** 31/05/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-atosiban-sun_en.pdf)

#### More information on Atosiban SUN

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/06/2024

## Share this page

[Back to top](#main-content)